Treatment Considerations in 3L mCRC

Northwestern Medicine Oncology and Hematology
Avatar

ASCO®, ESMO, and NCCN Guidelines on Treatment and Biomarker Testing/Selection in mCRC: How Do They Differ and What to Implement in Clinical Practice

By Northwestern Medicine Oncology and Hematology FEATURING Al Benson
By Northwestern Medicine Oncology and Hematology FEATURING Al Benson
585 views
September 18, 2023
0 Comments
Login to view comments. Click here to Login
34:29

Clinical Scenarios: Patient With Refractory mCRC and 3L Treatment Ap…

Katrina Pedersen

234 views
17:19

Year in Review: Colorectal Cancer

Moffitt Cancer Center

R. Kim, T. Biachi

2.1K views
21:24

Re-Challenge With Systemic Therapy for mCRC

Fred Hutchinson Cancer Center

[. Hsieh

367 views
23:27

ESMO 2023 Summary: "GI Key Studies Including MATTERHORN & KEYNOTE-81…

Insights from 2023 ESMO Annual Meeting

R. Kim, R. Mehta

615 views
16:39

Treatment of mCRC After Standard Chemotherapy

UChicago Medicine

A. Shergill

437 views
25:12

IO and Targeted Therapy in mCRC

2023 Evolution Conference

L. Connell

311 views
13:35

ESMO 2023 Summary: "Gastrointestinal Tumors - Lower Digestive Update…

Insights from 2023 ESMO Annual Meeting

R. Dienstmann

230 views
14:34

Treatment of Colon Cancer Beyond Second to Third Line

Mike Cusnir

324 views
10:26

Phase 3 Randomized SUNLIGHT Study: Trifluridine/Tipiracil + Bevacizu…

ASCO GI 2023 Conference Coverage

J. Tabernero

533 views
22:39

2023 Case-Based Clinical Updates in CRC

Total Health

E. Mitchell

242 views